Oncothyreon Acquires ‘Protocell’ Maker Alpine Biosciences for $27 Million

Oncothyreon Inc., a Seattle-based biotechnology company that specializes in developing treatments for cancer, said Aug. 11 that it has acquired another biotech that develops “protocells” to target the delivery of multiple therapeutic agents in a stock deal worth $27 million.

The company said that through its acquisition of Alpine Biosciences Inc., which also is based in Seattle, it intends to use the protocell technology to develop new product candidates for treating cancer and rare diseases.

Oncothyreon President and Chief Executive Officer Robert L. Kirkman said in the announcement, “The acquisition is a significant step towards achieving our vision of building ...